Globally, Lupin is the 7th largest in terms of market capitalization and 9th largest in terms of sales in Generic drugs. It is the 3rd largest pharma company in India in terms of revenue

Lupin’s API division has made rapid progress in growing its value-added formulation business, its Principal-to-Principal (P2P) business as well as its Global Institutional Business (GIB).

Lupin’s P2P business launched several first-to-market products in India and emerged as a b reliable supplier partner. Lupin continues to be a top supplier of AntiTB products to the World Health Organization’s Global Drug Facility (WHO)The US Food and Drug Administration (FDA) have given an all clear report recently to Lupin’s Mandideep unit which was recently under observation from March 2016. That is a boost for the company since Mandideep unit contributes 15 – 20 percent of US revenues.

On the financial performance side, the Q4FY16 has been another winning quarter for Lupin with overall b performance.On quarterly basis the company’s net revenue from operations reached to Rs.4181.16 crore in Q4FY16 compared to Rs.3078.15 crore in Q4FY2015 an increase of 35.83%. The operating profit for the quarter stood at Rs 1222.82 crore compared to Rs 682.22 crore same periods last year. Net profit for the quarter stood at Rs.807.08 crore compared to Rs. 547.01 crore.
For the year ended March 31, 2016 Lupin on consolidated basis reported net profit of Rs. 2270.69 crore compared to Rs.2403.24 crore FY2015 declining by 5.50% YOY, this decline in net profit is due to increase in expenditure and decline of other income.